Identification of New Toxicity Mechanisms in Drug-Induced Liver Injury Through Systems Pharmacology

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2022 Jul 27

PMID 35886075

Authors

Aurelio A Moya-Garcia

Andres Gonzalez-Jimenez

Fernando Moreno

Camilla Stephens

Maria Isabel Lucena

Juan A G Ranea

Affiliations

Soon will be listed here.

Abstract

Among adverse drug reactions, drug-induced liver injury presents particular challenges because of its complexity, and the underlying mechanisms are still not completely characterized. Our knowledge of the topic is limited and based on the assumption that a drug acts on one molecular target. We have leveraged drug polypharmacology, i.e., the ability of a drug to bind multiple targets and thus perturb several biological processes, to develop a systems pharmacology platform that integrates all drug-target interactions. Our analysis sheds light on the molecular mechanisms of drugs involved in drug-induced liver injury and provides new hypotheses to study this phenomenon.

References

Mondal S, Raja K, Schweizer U, Mugesh G . Chemistry and Biology in the Biosynthesis and Action of Thyroid Hormones. Angew Chem Int Ed Engl. 2016; 55(27):7606-30. DOI: 10.1002/anie.201601116. View

Fuxman Bass J, Diallo A, Nelson J, Soto J, Myers C, Walhout A . Using networks to measure similarity between genes: association index selection. Nat Methods. 2013; 10(12):1169-76. PMC: 3959882. DOI: 10.1038/nmeth.2728. View

Massberg D, Simon A, Haussinger D, Keitel V, Gisselmann G, Conrad H . Monoterpene (-)-citronellal affects hepatocarcinoma cell signaling via an olfactory receptor. Arch Biochem Biophys. 2014; 566:100-9. DOI: 10.1016/j.abb.2014.12.004. View

Aithal G, Ramsay L, Daly A, Sonchit N, Leathart J, Alexander G . Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology. 2004; 39(5):1430-40. DOI: 10.1002/hep.20205. View

Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N . Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. 2016; 17(4):372-377. DOI: 10.1038/tpj.2016.26. View

Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View

Andrade R, Lucena M, Fernandez M, Pelaez G, Pachkoria K, Garcia-Ruiz E . Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2):512-21. DOI: 10.1016/j.gastro.2005.05.006. View

De Martin E, Michot J, Rosmorduc O, Guettier C, Samuel D . Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. JHEP Rep. 2020; 2(6):100170. PMC: 7648167. DOI: 10.1016/j.jhepr.2020.100170. View

Andrade R, Lucena M, Alonso A, Garcia-Cortes M, Garcia-Ruiz E, Benitez R . HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004; 39(6):1603-12. DOI: 10.1002/hep.20215. View

10.

Seo M, Oh D . Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis. Prog Lipid Res. 2017; 66:50-68. DOI: 10.1016/j.plipres.2017.04.003. View

11.

Lucena M, Andrade R, Martinez C, Ulzurrun E, Garcia-Martin E, Borraz Y . Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology. 2008; 48(2):588-96. DOI: 10.1002/hep.22370. View

12.

Bailey M, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A . Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 2018; 173(2):371-385.e18. PMC: 6029450. DOI: 10.1016/j.cell.2018.02.060. View

13.

Stephens C, Castiella A, Gomez-Moreno E, Otazua P, Lopez-Nevot M, Zapata E . Autoantibody presentation in drug-induced liver injury and idiopathic autoimmune hepatitis: the influence of human leucocyte antigen alleles. Pharmacogenet Genomics. 2016; 26(9):414-22. DOI: 10.1097/FPC.0000000000000230. View

14.

Bouvy J, De Bruin M, Koopmanschap M . Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015; 38(5):437-53. PMC: 4412588. DOI: 10.1007/s40264-015-0281-0. View

15.

Bolognesi M . Harnessing Polypharmacology with Medicinal Chemistry. ACS Med Chem Lett. 2019; 10(3):273-275. PMC: 6421528. DOI: 10.1021/acsmedchemlett.9b00039. View

16.

Oliva-Vilarnau N, Hankeova S, Vorrink S, Mkrtchian S, Andersson E, Lauschke V . Calcium Signaling in Liver Injury and Regeneration. Front Med (Lausanne). 2018; 5:192. PMC: 6039545. DOI: 10.3389/fmed.2018.00192. View

17.

Kruger F, Gaulton A, Nowotka M, Overington J . PPDMs-a resource for mapping small molecule bioactivities from ChEMBL to Pfam-A protein domains. Bioinformatics. 2014; 31(5):776-8. PMC: 4341065. DOI: 10.1093/bioinformatics/btu711. View

18.

Morgan R, van Staden C, Chen Y, Kalyanaraman N, Kalanzi J, Dunn 2nd R . A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013; 136(1):216-41. DOI: 10.1093/toxsci/kft176. View

19.

Kuhn M, Al Banchaabouchi M, Campillos M, Jensen L, Gross C, Gavin A . Systematic identification of proteins that elicit drug side effects. Mol Syst Biol. 2013; 9:663. PMC: 3693830. DOI: 10.1038/msb.2013.10. View

20.

Ahn Y, Bagrow J, Lehmann S . Link communities reveal multiscale complexity in networks. Nature. 2010; 466(7307):761-4. DOI: 10.1038/nature09182. View